Profilaxia pós-exposição à hanseníase: mapa de evidências
DOI:
https://doi.org/10.34019/2446-5739.2026.v12.49173Palavras-chave:
Hanseníase, Profilaxia Pós-Exposição, Prática Clínica Baseada em EvidênciaResumo
Objetivo: Mapear evidências sobre a profilaxia pós-exposição à hanseníase por meio de síntese gráfica dos efeitos e níveis de exposição. Método: Mapa de evidências construído a partir de buscas nas bases BVS, Cochrane, Web of Science, Embase, PubMed e Scopus, realizadas entre outubro de 2020 e outubro de 2021. Foram incluídas revisões que avaliaram a eficácia da profilaxia pós-exposição, excluindo estudos com participantes sintomáticos. Procedeu-se à avaliação crítica, caracterização e representação gráfica dos estudos. Resultados: Sete revisões foram incluídas, analisando quimioprofilaxia, imunoprofilaxia e a combinação entre ambas. As evidências apontaram resultados positivos ou potencialmente positivos. Seis estudos apresentaram qualidade da evidência criticamente baixa, e um, baixa. Conclusão: Há evidências favoráveis à efetividade da intervenção avaliada. No entanto, destaca-se a necessidade de novas pesquisas com maior rigor metodológico.
ABSTRACT
Objective: To map evidence on post-exposure prophylaxis for leprosy through a graphical synthesis of effects and exposure levels. Method: Evidence map developed based on searches conducted between October 2020 and October 2021 in the VHL, Cochrane, Web of Science, Embase, PubMed, and Scopus databases. Reviews that assessed the effectiveness of post-exposure prophylaxis were included, while studies involving symptomatic participants were excluded. Critical appraisal, characterization, and graphical representation of studies were carried out. Results: Seven reviews were included, analyzing chemoprophylaxis, immunoprophylaxis, and their combination. Evidence showed positive or potentially positive results. Six studies presented critically low-quality evidence, and one was rated as low quality. Conclusion: There is favorable evidence supporting the effectiveness of the assessed intervention. However, further research with greater methodological rigor is needed.
Downloads
Referências
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Protocolo Clínico e Diretrizes Terapêuticas da Hanseníase [internet]. Brasília: Ministério da Saúde, 2022 [cited 2022 oct 10]. Available from: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/h/hanseniase/publicacoes/protocolo-clinico-e-diretrizes-terapeuticas-da-hanseniase-2022/view
World Health Organization. Weekly Epidemiological Record [Internet]. Genebra: WHO, 2024 [cited 2025 jun 10]; 99(37). Available from: https://iris.who.int/handle/10665/378893
World Health Organization. Towards zero leprosy: global leprosy (Hansen’s disease) strategy 2021–2030. Genebra: World Health Organization; 2021 [cited 2022 oct 10]. Available from: https://www.who.int/publications/i/item/9789290228509
Smith CM, Smith WC. Chemoprophylaxis is effective in the prevention of leprosy in endemic countries: a systematic review and meta-analysis. MILEP2 Study Group. Mucosal Immunology of Leprosy. J Infect [internet]. 2000 [cited 2022 oct 10]; 41(2). Available from: https://doi.org/10.1053/jinf.2000.0698
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Quimioprofilaxia de contatos de doentes de hanseníase com rifampicina em dose única [Internet]. Brasília: Ministério da Saúde, 2015 [cited 2022 oct 10]. Available from: https://docs.bvsalud.org/biblioref/2017/11/874922/relatorio_quimioprofilaxia_hanseniase_final.pdf
Schoenmakers A, Mieras L, Budiawan T, Van Brakel WH. The state of affairs in post-exposure leprosy prevention: a descriptive meta-analysis on immuno- and chemo-prophylaxis. Res Rep Trop Med [Internet]. 2020 [cited 2022 oct 20];11. Available from: https://doi.org/10.2147/RRTM.S190300
Ferreira SMB, Yonekura T, Ignotti E, Oliveira LB, Takahashi J, Soares CB. Effectiveness of rifampicin chemoprophylaxis in preventing leprosy in patient contacts: a systematic review of quantitative and qualitative evidence. JBI Database System Rev Implement Rep [Internet]. 2017 [cited 2022 oct 10];15(10). Available from: https://doi.org/10.11124/JBISRIR-2016-003301
Fundação Oswaldo Cruz. Mapas de evidências: metodologia e aplicação [Internet]. Rio de Janeiro: Campus Virtual Fiocruz, 2020 [cited 2022 oct 10]. Available from: https://campusvirtual.fiocruz.br/portal/?q=noticia/60004
Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde. Mapas de evidências: conceito e metodologia [Internet]. São Paulo: BIREME/OPAS/OMS, 2020. [cited 2022 oct 20]. Avaliable from: https://red.bvsalud.org/mapasdeevidencias-2/
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ [Internet]. 2017 [cited 2025 Sep 11. Available from: https://doi.org/10.1136/bmj.j4008
PRISMA 2020. Flow diagram: transparent reporting of systematic reviews and meta-analyses [Internet]. Melbourne: PRISMA, 2020 [cited 2024 Dec 02]. Available from: https://www.prisma-statement.org/prisma-2020-flow-diagram
Reveiz L, Buendía JA, Téllez D. Chemoprophylaxis in contacts of patients with leprosy: systematic review and meta-analysis. Rev Panam Salud Publica [Internet]. 2009 [Cited 10 oct 2022]; 26(4). Available from: https://doi.org.10.1590/s1020-49892009001000009.
Smith WC, Saunderson P. Leprosy. BMJ Clin Evid [Internet]. 2010 [cited 2024 Dec 3]. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3217821/
Asyura M, Wijaya IR, Toshukowong T, Wang RS. Effectiveness analysis of single dose rifampicin post-exposure prophylaxis (SDR-PEP) as a preventive intervention for leprosy transmission: a systematic review of randomized controlled trials. J Public Health Trop Coast.Reg [Internet]. 2021 [cited 2022 oct 10] ;4(2). Available from: https://doi.org.10.14710/jphtcr.v4i2.10794.
Mulianto N, Sari ADAP, Kariosentono H, Arrochman F, Margiana R. A systematic review of the importance of chemoprophylaxis and immunoprophylaxis in subclinical cases of leprosy that can reduce the incidence and transmission of leprosy. Eur J Mol Clin Med [Internet]. 2020 [ cited 2022 oct 10];7(11). Available from: https://scholar.ui.ac.id/en/publications/a-systematic-review-of-the-importance-of-chemoprophylaxis-and-imm
Ferreira SMB, Yonekura T, Ignotti E, Oliveira LB, Takahashi J, Soares CB. Effectiveness of rifampicin chemoprophylaxis in preventing leprosy in patient contacts: a systematic review of quantitative and qualitative evidence. JBI Database System Rev Implement Rep [Internet]. 2017 [cited 2022 oct 10];15(10). Available from: https://doi.org.10.11124/JBISRIR-2016-003301.
Bogado AC, Rosas FS, Oliveira EFT. Análise das coautorias entre Brasil e demais países em hanseníase: um olhar a partir do Instituto Lauro de Souza Lima. Proceedings of the 8th Bibliotecometria e Cientometria [Internet]. 2022 [cited 2022 oct 10]. Available from: https://www.researchgate.net/publication/362253966_Analise_das_coautorias_entre_Brasil_e_demais_paises_em_hanseniase_um_olhar_a_partir_do_Instituto_Lauro_de_Souza_Lima
Richardus JH, Tiwari A, Barth-Jaeggi T, Arif MA, Banstola NL, Baskota R, et al. Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): an international feasibility programme. Lancet Glob Health [Internet]. 2021 [Cited 2022 oct 20] ;9(1). Available from: https://doi.org.10.1016/S2214-109X(20)30396-X.
Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em Saúde. Departamento de Gestão e Incorporação de Tecnologias e Inovação em Saúde. Exclusão da rifampicina para quimioprofilaxia de contatos de pacientes com hanseníase [Internet]. Brasília: Ministério da Saúde; 2020 [Cited 2022 set 08]. Available from: https://docs.bvsalud.org/biblioref/2020/10/1121396/relatorio_rifampicina_quimioprofilaxia_hansenase_525_2020_final.pdf
Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, et al. An Enhanced Regimen as Post-Exposure Chemoprophylaxis for Leprosy: PEP+. BMC Infect Dis [Internet]. 2018 [Cited 2022 oct 20];18(1). Available from https://doi.org.10.1186/s12879-018-3402-4.
Moet FJ, Pahan D, Oskam L, Richardus JH; COLEP Study Group. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ [Internet]. 2008 [Cited 2022 oct 20]; 336(7647). Available from: https://doi.org.10.1136/bmj.39500.885752.BE.
Saunderson P. Approaches and challenges in the prevention of leprosy. Ethiopian Med J [Internet]. 2019 [Cited 2022 oct 10];57(1). Available from: https://www.emjema.org/index.php/EMJ/article/view/1206/pdf_209
Wang L, Wang H, Yan L, Yu M, Yang J, Li J, et al. Single-dose rifapentine in household contacts of patients with leprosy. N Engl J Med [Internet]. 2023 [Cited 2022 oct 10];388(20). Available from: https://doi.org.10.1056/NEJMoa2205487.
Tiwari A, Blok DJ, Arif M, Richardus JH. Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis. PLoS Negl Trop Dis [Internet]. 2020 [Cited 2022 oct 10];14(8). Available from: https://doi.org.10.1371/journal.pntd.0008521.
Campbell PO, Douglas NM, Chambers ST. A review of the efficacy, safety, and feasibility of rifamycin-based post-exposure chemoprophylaxis for leprosy. Trop Med Infect Dis [Internet]. 2025 [cited 2026 Jan 19];10(4):84. Available from: https://doi.org/10.3390/tropicalmed10040084
Richardus JH, Mieras L, Saunderson P, Ignotti E, Virmond M, Arif MA, et al. Leprosy post-exposure prophylaxis risks not adequately assessed - Author's reply. Lancet Glob Health [Internet]. 2021 [Cited 2022 oct 201;9(4) Available from: https://doi.org.10.1016/S2214-109X(21)00047-4.
Li X, Ma Y, Li G, Jin G, Xu L, Li Y, et al. Leprosy: treatment, prevention, immune response and gene function. Front Immunol [Internet]. 2024 [cited 2026 jan 10]; 15:1298749. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1298749/full
Duthie MS, Balagon MF. Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy. Risk Manag Healthc Policy [Internet]. 2016 [Cited 2022 oct 10];9. Available from: https://doi.org.10.2147/RMHP.S76058.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ [Internet]. 2017 [Cited 2022 oct 10]; 358. Available from: https://doi.org.10.1136/bmj.j4008.
Ministério da Saúde (BR). Secretaria de Vigilância em Saúde e Ambiente. Demandas de pesquisas para apoio à gestão da Secretaria de Vigilância em Saúde e Ambiente [Internet]. Brasília: Ministério da Saúde; 2025 [cited 2025 Mar 25]. Available em: https://bvsms.saude.gov.br/bvs/publicacoes/demandas_pesquisa_apoio_gestao_svsa.pdf
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2026 Gabrielle Guedes Pedroso, Ana Carolina Vidigal Vieira Ferreira, Maria Luiza Quintiliano, Sarah Lamas Vidal, Gesner Francisco Xavier, Fernanda Moura Lanza, Angélica da Conceição Oliveira Coelho
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
